drugset / Trial / NCT05741242

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

NCT05741242

Phase 1/2 Enrolling by invitation 136 enrolled Jaime Leandro Foundation for Therapeutic Cancer Vaccines
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Timeline

Start
2022-11-30
Primary completion
2027-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Personalized Synthetic Long Peptide Vaccine Vaccine

Indications